Interestingly, C-75 is an inhibitor of FAS which triggers apoptosis during S phase and inhibits fatty acids synthesis in liver cancer [40, 41], which might be an effective targeted therapy of ccRCC. This evidence concerns the gene FAS and nonpapillary renal cell carcinoma.